XTL Biopharmaceuticals Ltd. (TLV:XTLB)
2.200
0.00 (0.00%)
At close: Jan 9, 2026
XTL Biopharmaceuticals Revenue
XTL Biopharmaceuticals had revenue of $258.50K USD in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $968.00K. In the year 2024, XTL Biopharmaceuticals had annual revenue of $451.00K.
Revenue (ttm)
$968.00K
Revenue Growth
n/a
P/S Ratio
6.38
Revenue / Employee
$96.80K
Employees
10
Market Cap
20.82M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 451.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.87B |
| Novolog (Pharm-Up 1966) | 1.97B |
| Ilex Medical | 917.10M |
| Kamada | 578.74M |
| SofWave Medical | 255.13M |
| BrainsWay | 162.56M |
| Bait Bakfar | 107.78M |
XTL Biopharmaceuticals News
- 17 days ago - XTL Biopharmaceuticals receives Nasdaq bid price deficiency notice - Seeking Alpha
- 17 days ago - XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency - GlobeNewsWire
- 9 months ago - XTL Names Mr. Noam Band as its New Chief Executive Officer - GlobeNewsWire
- 1 year ago - XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million - GlobeNewsWire
- 1 year ago - XTL Entered Definitive Agreement to Acquire The Social Proxy - GlobeNewsWire
- 1 year ago - XTL To Aquire The Social Proxy - GlobeNewsWire
- 2 years ago - XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel - GlobeNewsWire
- 2 years ago - XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewsWire